Satellos Bioscience
MSLE
26 hedge funds and large institutions have $59.6M invested in Satellos Bioscience in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 7 closing their positions.
39% more capital invested
Capital invested by funds: $42.8M → $59.6M (+$16.8M)
0.06% more ownership
Funds ownership: 36.83% → 36.89% (+0.06%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
16% less funds holding
Funds holding: 31 → 26 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$2.69M |
| 2 |
AIC
AWM Investment Company
New York
|
+$1.24M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.12M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$173K |
| 5 |
CUAMC
China Universal Asset Management Company
Shanghai,
China
|
+$93.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.58M |
| 2 |
Millennium Management
New York
|
-$1M |
| 3 |
EAM
Empery Asset Management
New York
|
-$845K |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$687K |
| 5 |
HF
HRT Financial
New York
|
-$171K |
MSLE Hedge Fund Activity: Q2 2026 in Review
26 of the 8,300 institutional investors tracked by Wall St. Rank reported a position in Satellos Bioscience (MSLE) for Q2 2026, worth a combined $59.6M — up 39% from $42.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of MSLE and 2 opened new positions — a net loss of 5 holders — while 6 trimmed existing stakes and 6 added.
The largest buyer was Stonepine Capital Management, adding an estimated $2.69M. The largest seller was Adage Capital Partners, cutting an estimated $1.58M.
- 26 institutional investors held Satellos Bioscience (MSLE) as of Q2 2026, down from 31 in Q1 2026.
- Funds reported $59.6M of Satellos Bioscience stock for Q2 2026, up 39% quarter-over-quarter.
- 2 funds opened new Satellos Bioscience positions in Q2 2026 and 7 closed out, a net change of -5 holders.
- The largest Satellos Bioscience buyer in Q2 2026 was Stonepine Capital Management, an estimated $2.69M added.
- The largest Satellos Bioscience seller in Q2 2026 was Adage Capital Partners, an estimated $1.58M sold.
Based on aggregated 13F filings for Q2 2026.